share_log

Arcutis Biotherapeutics | CORRESP: CORRESP

Arcutis Biotherapeutics | CORRESP: CORRESP

Arcutis Biotherapeutics | CORRESP：信函
美股sec公告 ·  01/24 14:37
Moomoo AI 已提取核心信息
Arcutis Biotherapeutics, Inc. has submitted an amendment to its Tender Offer Statement on Schedule TO, originally filed on January 16, 2024, in response to comments from the U.S. Securities and Exchange Commission (SEC). The amendment, known as Amendment No. 1, addresses concerns raised by the SEC in a letter dated January 23, 2024. The SEC's comments pertained to certain conditions in the offer that were considered too broad or lacking clarity. Specifically, Arcutis has revised the offer to remove references to limitations on prices for securities and certain broad conditions that could be triggered by general market changes or geopolitical events. The company also updated the timing for announcements related to the extension of the offer to comply with SEC rules. The correspondence, dated January 24, 2024, was facilitated by Latham & Watkins LLP on behalf of Arcutis Biotherapeutics.
Arcutis Biotherapeutics, Inc. has submitted an amendment to its Tender Offer Statement on Schedule TO, originally filed on January 16, 2024, in response to comments from the U.S. Securities and Exchange Commission (SEC). The amendment, known as Amendment No. 1, addresses concerns raised by the SEC in a letter dated January 23, 2024. The SEC's comments pertained to certain conditions in the offer that were considered too broad or lacking clarity. Specifically, Arcutis has revised the offer to remove references to limitations on prices for securities and certain broad conditions that could be triggered by general market changes or geopolitical events. The company also updated the timing for announcements related to the extension of the offer to comply with SEC rules. The correspondence, dated January 24, 2024, was facilitated by Latham & Watkins LLP on behalf of Arcutis Biotherapeutics.
针对美国证券交易委员会（SEC）的评论，Arcutis Biotherapeutics, Inc.已提交了对最初于2024年1月16日提交的附表期限的要约声明的修正案。该修正案被称为第1号修正案，解决了美国证券交易委员会在2024年1月23日的一封信中提出的担忧。美国证券交易委员会的评论与报价中的某些条件有关，这些条件被认为过于宽泛或不明确。具体而言，Arcutis修改了要约，删除了提及证券价格限制和某些可能由总体市场变化或地缘政治事件触发的广泛条件的提法。该公司还更新了与延长要约有关的公告时间，以遵守美国证券交易委员会的规定。该信函的日期为2024年1月24日，由瑞生律师事务所代表Arcutis Biotherapeutics提供便利。
针对美国证券交易委员会（SEC）的评论，Arcutis Biotherapeutics, Inc.已提交了对最初于2024年1月16日提交的附表期限的要约声明的修正案。该修正案被称为第1号修正案，解决了美国证券交易委员会在2024年1月23日的一封信中提出的担忧。美国证券交易委员会的评论与报价中的某些条件有关，这些条件被认为过于宽泛或不明确。具体而言，Arcutis修改了要约，删除了提及证券价格限制和某些可能由总体市场变化或地缘政治事件触发的广泛条件的提法。该公司还更新了与延长要约有关的公告时间，以遵守美国证券交易委员会的规定。该信函的日期为2024年1月24日，由瑞生律师事务所代表Arcutis Biotherapeutics提供便利。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息